![Addition of bevacizumab fails to benefit overall survival in newly diagnosed glioblastoma [RTOG 0825 trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/02/AFIP-00405558-Glioblastoma-Radiology-e1381685577283-350x250.jpg)
#VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Click here to read this study in NEJM.
©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
RelatedReports
